Is there any role for re-biopsy and NGS for patients with NSCLC and KRAS G12C at time of progression after first line therapy before starting sotorasib, or after progression on sotorasib?

This is a great question and one that will come up more frequently. There clearly is a role for biopsy at the time of progression on targeted therapies in other driver alterations in NSCLC, and in limited data; to date, we know that occasionally there are resistance mechanisms to KRAS inhibitors tha...